Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer | |
Wang, Jian-dong ; Shen, Jun ; Zhou, Xue-ping ; Shi, Wei-bin ; Yan, Jiang-hua ; Luo, Fang-hong ; Quan, Zhi-wei ; Yan JH(颜江华) ; Luo FH(罗芳洪) | |
刊名 | http://dx.doi.org/10.1007/s10103-012-1248-3 |
2013 | |
关键词 | TUMOR-MODEL IN-VIVO PHARMACOKINETICS TISSUE PHOTOSENSITIZER BIODISTRIBUTION EFFICACY QUANTIFICATION TEMOPORFIN EFFICIENCY |
英文摘要 | National "Eleventh Five-Year" special science and technology major project [2008ZX10002-025]; College Fund of Shanghai Jiaotong University School of Medicine [10XJ22003]; Photodynamic therapy (PDT) has been clinically used for liver cancer. The pharmacokinetics of a photosensitizer needs to be monitored so that PDT can be performed at the most favorable time and with the proper dose to increase the cure rate. As mTHPC is a fluorescent compound, we investigate its pharmacokinetics, distribution, and elimination in the rat orthotropic liver cancer model in order to confirm an optimal treatment opportunity of liver cancer PDT. After intravenous administration at a single dose of 300 mu g/kg, mTHPC was extracted from tissue homogenates or plasma. Then, mTHPC concentrations were assessed by fluorescence spectroscopy and the data were processed with PK-GRAPH pharmacokinetic procedure. The plasma concentration-time profile of mTHPC showed a short distribution half-life (TA1/2I +/- = 0.082 h) and a relatively longer elimination half-life (TA1/2I(2) = 28.23 h), which quite fitted with a two-compartment model. The results of mTHPC tissue distributions showed that the highest drug accumulation was in tumor tissue, and successively decreased in liver, heart, spleen, muscle, and skin tissues. The drug distribution ratio of tumor to normal tissue reached the peak at 24 h after mTHPC administration. mTHPC was eliminated at a suitable rate in rat orthotropic liver cancer model, and there was no long-term accumulation of mTHPC in rat tissues. For PDT of orthotropic liver cancer, 24 h after mTHPC intravenous injection may be the optimal treatment time point, which might provide higher clinical efficacy and reduce side effects. |
语种 | 英语 |
出版者 | SPRINGER LONDON LTD |
内容类型 | 期刊论文 |
源URL | [http://dspace.xmu.edu.cn/handle/2288/93463] |
专题 | 医学院-已发表论文 |
推荐引用方式 GB/T 7714 | Wang, Jian-dong,Shen, Jun,Zhou, Xue-ping,et al. Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer[J]. http://dx.doi.org/10.1007/s10103-012-1248-3,2013. |
APA | Wang, Jian-dong.,Shen, Jun.,Zhou, Xue-ping.,Shi, Wei-bin.,Yan, Jiang-hua.,...&罗芳洪.(2013).Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer.http://dx.doi.org/10.1007/s10103-012-1248-3. |
MLA | Wang, Jian-dong,et al."Optimal treatment opportunity for mTHPC-mediated photodynamic therapy of liver cancer".http://dx.doi.org/10.1007/s10103-012-1248-3 (2013). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论